

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:	Chapter 7
AKORN HOLDING COMPANY LLC, et al.,	Case No. 23-10253 (KBO)
Debtors. ¹	(Jointly Administered)
	Hearing Date: April 24, 2023 at 9:30 a.m. (ET)
	Objections Due: At or Before the Hearing
	RE: D.I. 102

**ETHYPHARM S.A.S.’S MOTION TO FILE UNDER SEAL ITS OBJECTION
TO TRUSTEE’S MOTION FOR ENTRY OF AN ORDER EXTENDING TIME
TO ASSUME OR REJECT EXECUTORY CONTRACTS AND UNEXPIRED
LEASES OF PERSONAL PROPERTY PURSUANT TO 11 U.S.C. § 365(d)(1)**

Ethypharm S.A.S. (“Ethypharm”), by and through its undersigned counsel, respectfully moves (this “**Motion**”) as follows:

RELIEF REQUESTED

1. Ethypharm seeks entry of an order, substantially in the form attached as Exhibit A, authorizing the filing under seal portions of (i) *Ethypharm S.A.S.’s Objection to Trustee’s Motion for Entry of an Order Extending Time to Assume or Reject Executory Contracts and Expired Leases of Personal Property Pursuant to 11 U.S.C. § 365(d)(1)* [D.I. 102] (the “**Objection**”)² and (ii) the declaration in support of the Objection attached as Exhibit A to the

¹ The Debtors in these chapter 7 cases, along with the last four digits of their federal tax identification numbers, and cases numbers are Akorn Holding Company LLC (9190), Case No. 23-10253 (KBO); Akorn Intermediate Company LLC (6123), Case No. 23-10254 (KBO); and Akorn Operating Company LLC (6184), Case No. 23-10255. The Debtors’ headquarters is located at 5605 CenterPoint Court, Gurnee, IL 60031.

² Capitalized terms used but not defined herein shall have the same meanings ascribed to such terms in the Objection.

Objection (including the exhibits thereto, the “**Declaration**”), and (iii) granting such other and further relief as the Court deems just and proper.

RELEVANT BACKGROUND

2. On February 23, 2023 (the “**Petition Date**”), each of the above-captioned debtors (collectively, the “**Debtors**”) filed a voluntary petition in the Bankruptcy Court for relief under chapter 7 of the Bankruptcy Code.

3. On or about the Petition Date, the Office of the United States Trustee appointed George L. Miller as the chapter 7 Trustee to the estates of each of the Debtors.

4. On April 7, 2023, the Trustee filed the *Trustee’s Motion for Entry of an Order Extending Time to Assume or Reject Executory Contracts and Expired Leases of Personal Property Pursuant to 11 U.S.C. § 365(d)(1)* [D.I. 77] (the “**Motion to Extend**”).

5. Contemporaneously with the filing of this Motion, Ethypharm filed the Objection to the Motion to Extend.

6. The Objection and the Declaration refer to certain confidential, commercially sensitive data (the “**Confidential Information**”) concerning Ethypharm’s business, including information regarding commercial contract terms and revenue. Ethypharm has redacted portions of the Objection and Declaration that contain or reference Confidential Information to avoid its public disclosure. In addition, the contracts between Ethypharm and the Debtors (collectively, the “**Agreements**”), which are attached as exhibits to the Declaration, include confidentiality provisions and commercially sensitive information requiring that the Agreements be sealed in their entirety. Ethypharm seeks the entry of an Order, substantially in the form attached hereto as **Exhibit A** (the “**Proposed Order**”), permitting Ethypharm to file the unredacted portions of the Objection and Declaration under seal and permitting the Agreements to be sealed in their entirety.

BASIS FOR RELIEF

6. Section 107(b)(1) provides that “[o]n request of a party in interest, the bankruptcy court shall . . . protect an entity with respect to a trade secret or confidential research, development, or commercial information” 11 U.S.C. § 107(b). Section 107(b) of the Bankruptcy Code does not require the entity seeking protection to demonstrate “good cause.” *See Video Software Dealers Ass’n v. Orion Pictures Corp. (In re Orion Pictures Corp.)*, 21 F.3d 24, 28 (2d Cir. 1994). Rather, if the material sought to be protected satisfies one of the categories identified in section 107(b) of the Bankruptcy Code, a court is required to protect the requesting party and has no discretion to deny the request. *Id.* at 27 (holding that, once the court determines that a party is seeking protection of information that falls within the ambit of section 107(b) of the Bankruptcy Code, “the court is required to protect a requesting interested party and has no discretion to deny the application”).

7. Thus, under section 107(b) of the Bankruptcy Code, an interested party need only show that the information it wishes to protect is “‘confidential’ and ‘commercial’ in nature.” *Id.* In granting motions to seal “commercial information,” courts have defined this term as information that would, “if subject to disclosure, [] ‘unfairly benefit’ that entity’s competitors.” *In re Allegriy, Inc.*, No. 15-10226 (LSS), 2015 WL 10963572, at *3 (Bankr. D. Del. July 6, 2015). Courts have held that disclosure of information that provides insight into an entity’s “strategic decision making” could unfairly benefit its competitors and should be sealed. *See In re Dreier LLP*, 485 B.R. 821, 823 (Bankr. S.D.N.Y. 2013) (sealing excerpt of deposition transcript of hedge fund manager wherein he described how investments were made, finding that disclosure of this “strategic decision making” would provide an unfair advantage to competitors); *In re Am. Bus. Fin. Services, Inc.*, No. 05-10203 MFW, 2008 WL 3906894, at *4 (Bankr. D. Del. Aug. 20, 2008)

(sealing credit committee's analysis of credit applications because disclosure of such information could enable competitors to capitalize on the committee's knowledge and experience). The information, however, need not rise to the level of a trade secret to be protected under section 107(b) of the Bankruptcy Code. *See Orion Pictures*, 21 F.3d at 28.

8. The Confidential Information is both "commercial" and "confidential," thus warranting protection under section 107(b). Disclosure of the Confidential Information could reveal to Ethypharm's competitors sensitive information about Ethypharm's commercial operations in the United States and globally. Such "strategic decision making" is confidential commercial information warranting protection under section 107(b). *See In re Dreir*, 485 B.R. at 823; *In re Am. Bus. Fin. Servives, Inc.*, 2008 WL 3906894, at *4. Ethypharm has attempted to narrowly tailor the Confidential Information that it proposes maintaining under seal.

AVERMENT REGARDING COMPLIANCE WITH LOCAL RULE 9018-1(d)

9. Consistent with Local Rule 9018-1(d)(iv)(e), to the best of the knowledge, information and belief of counsel to Ethypharm, the Objection does not contain information subject to confidentiality rights of another holder of confidentiality rights.

NOTICE

10. Notice of this Motion is being provided through the Court's CM/ECF electronic noticing system to all parties that have requested notice in these cases. A courtesy copy will also be emailed to counsel to the Trustee, and the U.S. Trustee.

[Remainder intentionally left blank]

CONCLUSION

WHEREFORE, Ethypharm respectfully requests that this Court enter an order in substantially the form attached hereto as **Exhibit A** granting the relief requested in this Motion and granting such further relief as the Court may deem necessary or proper.

Dated: April 21, 2023
Wilmington, Delaware

/s/ Curtis S. Miller

BAKER BOTTS L.L.P.

Scott R. Bowling (*pro hac vice* pending)
30 Rockefeller Plaza
New York, New York 10112
Telephone: (212) 408-2500
Facsimile: (212) 259-2501
Email: scott.bowling@bakerbotts.com

-and-

BAKER BOTTS L.L.P.

Kevin Chiu (*pro hac vice* pending)
2001 Ross Avenue, Suite 900
Dallas, Texas 75201-2980
Telephone: (214) 953-6500
Facsimile: (214) 953-6503
Email: kevin.chiu@bakerbotts.com

MORRIS, NICHOLS, ARSHT & TUNNELL

LLP
Curtis S. Miller (No. 4583)
Andrew R. Remming (No. 5120)
1201 N. Market Street, 16th Floor
P.O. Box 1347
Wilmington, Delaware 19899-1347
Telephone: (302) 658-9200
Facsimile: (302) 658-3989
Email: cmiller@ morrisnichols.com
aremming@ morrisnichols.com

Attorneys for Ethypharm S.A.S.